Previous in-vitro data pointed out lithium, an activator of the β-catenin signalling pathway, as a modulator of HIV-1 transcription. We assessed the effect of in-vivo administration of lithium on viral latency modulation in nine antiretroviral therapy (ART)-suppressed HIV-1-infected individuals. We found that lithium carbonate treatment was able to transiently repress HIV-1 residual expression in CD4+ T cells in vivo, which led to a concomitant short-term decrease in the proviral reservoir size. © 2014 Wolters Kluwer Health.
|Publication status||Published - 1 Jan 2014|